Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/PD-L1 inhibitors plus gemcitabine/cisplatin vs gemcitabine/cisplatin for advanced intrahepatic cholangiocarcinoma (retrospective cohort)
ChiCTR2600117218Phase 4Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoints: Overall survival, Progression-free survival (median PFS) and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2600117218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117218.